Reported Earnings • Aug 16
Second quarter 2026 earnings released: US$0.12 loss per share (vs US$0.049 profit in 2Q 2025) Second quarter 2026 results: US$0.12 loss per share (down from US$0.049 profit in 2Q 2025). Revenue: US$7.02m (up 24% from 2Q 2025). Net loss: US$219.0k (down 396% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth. お知らせ • Aug 01
Precipio, Inc. to Report Q2, 2026 Results on Aug 17, 2026 Precipio, Inc. announced that they will report Q2, 2026 results on Aug 17, 2026 Recent Insider Transactions Derivative • May 20
Independent Chairman of the Board notifies of intention to sell stock Richard Sandberg intends to sell 4k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$24.85, it would amount to US$100k. Since June 2025, Richard has owned 75.35k shares directly. Company insiders have collectively sold US$28k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • May 17
First quarter 2026 earnings released: US$0.81 loss per share (vs US$0.59 loss in 1Q 2025) First quarter 2026 results: US$0.81 loss per share (further deteriorated from US$0.59 loss in 1Q 2025). Revenue: US$6.71m (up 36% from 1Q 2025). Net loss: US$1.44m (loss widened 63% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. お知らせ • Apr 29
Precipio, Inc., Annual General Meeting, Jun 15, 2026 Precipio, Inc., Annual General Meeting, Jun 15, 2026. Reported Earnings • Mar 31
Full year 2025 earnings released: US$0.23 loss per share (vs US$2.93 loss in FY 2024) Full year 2025 results: US$0.23 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$24.0m (up 30% from FY 2024). Net loss: US$363.0k (loss narrowed 92% from FY 2024). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. お知らせ • Mar 11
Precipio Inc Announces Bloodhound BCR::ABL1 Assay For Chronic Myeloid Leukemia Precipio, Inc. has announced the publication in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio’s new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). The study analyzed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML, and underscores the key advantage of a single assay that delivers multiple, medically relevant data points simultaneously. The assay can be run in physician office laboratories, regional laboratories and hospitals. The study demonstrates that 25% of patients have multiple forms of BCR::ABL1 breakpoints that are missed because looking for all four requires laboratories to run four different assays (isoforms p190, p210, p230 and p203). No other test delivers all results from the same platform at the same time. Quantitative results for BCR::ABL breakpoints are crucial for the management of CML, providing clinicians a precise, standardized measurement of the disease burden, thereby enabling them to monitor the impact of treatment and detect early relapse. Current assays on the market provide quantitative results only for one breakpoint, p210 (also called “Major transcript”), using an established International Standard (IS) scale. The absence of quantified results for all four breakpoints hinders clinicians' ability to adequately monitor patients if other isoforms other than p210 indicate recurrence. Precipio’s Bloodhound BCR::ABL assay can detect changes as low as 1 in 100,000 cells (0.001%), thereby making it a powerful tool for monitoring measurable residual disease (MRD). At these low levels, early trends in these isoforms can provide months of advanced warning time that other, less sensitive or qualitative assays may not detect. The diagnosis and therapeutic decision-making in CML depend on the detection and quantification of BCR::ABL1. Until now, no clinical assay existed that could simultaneously test multiple BCR::ABL1 isoforms and provide quantified results, therefore requiring laboratories to run separate tests for each isoform. To address this challenge, Precipio developed the BloodHound assay, enabling laboratories to provide proper, comprehensive testing for CML patients. The assay runs all 4 breakpoints on a single, pre-plated plate run (with all controls provided) on a RT-PCR machine. Precipio’s custom-developed analysis software provides fully quantified automated results including molecular response criteria. The BCR::ABL1 test provides important diagnostic criteria for patients with AML, ALL and MPN. The new Precipio test simplifies workflow into one assay, is standardizable across laboratories, is quantitative and, importantly, provides target genetic markers to enable monitoring disease for years over the treatment course. お知らせ • Dec 05
Precipio, Inc. to Showcase Its BCR::ABL1 Panel At 2025 Ash (American Society of Hematology) Meeting Precipio, Inc. will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows. New Risk • Nov 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Significant insider selling over the past 3 months (US$123k sold). Market cap is less than US$100m (US$42.9m market cap). Reported Earnings • Nov 17
Third quarter 2025 earnings released: US$0.048 loss per share (vs US$0.42 loss in 3Q 2024) Third quarter 2025 results: US$0.048 loss per share (improved from US$0.42 loss in 3Q 2024). Revenue: US$6.77m (up 30% from 3Q 2024). Net loss: US$79.0k (loss narrowed 87% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. New Risk • Oct 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$123k sold). Market cap is less than US$100m (US$28.8m market cap). お知らせ • Sep 04
Precipio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $1.061478 million. Precipio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $1.061478 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Aug 14
Second quarter 2025 earnings released: EPS: US$0.049 (vs US$0.83 loss in 2Q 2024) Second quarter 2025 results: EPS: US$0.049 (up from US$0.83 loss in 2Q 2024). Revenue: US$5.65m (up 27% from 2Q 2024). Net income: US$74.0k (up US$1.29m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Recent Insider Transactions • May 25
Independent Chairman of the Board recently bought US$74k worth of stock On the 21st of May, Richard Sandberg bought around 8k shares on-market at roughly US$9.27 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of US$125k worth in shares. Reported Earnings • May 15
First quarter 2025 earnings released: US$0.59 loss per share (vs US$1.46 loss in 1Q 2024) First quarter 2025 results: US$0.59 loss per share (improved from US$1.46 loss in 1Q 2024). Revenue: US$4.93m (up 44% from 1Q 2024). Net loss: US$884.0k (loss narrowed 57% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. お知らせ • May 01
Precipio, Inc., Annual General Meeting, Jun 17, 2025 Precipio, Inc., Annual General Meeting, Jun 17, 2025. New Risk • Apr 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (US$8.20m market cap). Reported Earnings • Mar 28
Full year 2024 earnings released: US$2.93 loss per share (vs US$4.51 loss in FY 2023) Full year 2024 results: US$2.93 loss per share (improved from US$4.51 loss in FY 2023). Revenue: US$18.5m (up 22% from FY 2023). Net loss: US$4.29m (loss narrowed 27% from FY 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. New Risk • Feb 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$11.9m market cap). Recent Insider Transactions • Dec 16
Independent Chairman of the Board recently bought US$87k worth of stock On the 13th of December, Richard Sandberg bought around 15k shares on-market at roughly US$5.80 per share. This transaction increased Richard's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of US$13k worth in shares. Recent Insider Transactions Derivative • Dec 12
Independent Chairman of the Board notifies of intention to sell stock Richard Sandberg intends to sell 14k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$5.90, it would amount to US$83k. Since June 2024, Richard's direct individual holding has decreased from 16.03k shares to 42.00. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Reported Earnings • Nov 08
Third quarter 2024 earnings released: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023) Third quarter 2024 results: US$0.42 loss per share (improved from US$1.04 loss in 3Q 2023). Revenue: US$5.21m (up 15% from 3Q 2023). Net loss: US$626.0k (loss narrowed 57% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. お知らせ • Oct 09
Precipio Expands Bloodhound MPN Panel by Adding CALR Mutation Subtyping Precipio, Inc. announced the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024--August 8, 2024). This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN. The inclusion of CALR mutation subtyping is a direct response to the evolving landscape of MPN patient care where understanding the specific type of CALR mutation can influence treatment strategies and outcomes. The CALR gene mutation is prevalent in various myeloproliferative neoplasms and plays a critical role in disease prognosis and therapeutic decision-making. The distinction between CALR type1 and type 2 can indicate the severity of disease progression (prognosis) and inform the physician on the specific treatment needed to suit the patient's situation. Furthermore, for patients with dual mutations (e.g. JAK2 & CALR), the identification of the subtype CALR mutation present can impact the selection of targeted therapies. With the recent updates from the NCCN, healthcare providers are looking for more detailed information regarding CALR mutations, allowing them to better manage MPN patient care. Precipio's new Bloodhound MPN assay provides them with exactly what they need to help specify an MPN subtype and to determine which CALR-positive patients may respond to CALR-targeted therapies. Reported Earnings • Aug 15
Second quarter 2024 earnings released: US$0.83 loss per share (vs US$1.88 loss in 2Q 2023) Second quarter 2024 results: US$0.83 loss per share (improved from US$1.88 loss in 2Q 2023). Revenue: US$4.44m (up 26% from 2Q 2023). Net loss: US$1.22m (loss narrowed 47% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. New Risk • Jul 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.8m free cash flow). Market cap is less than US$10m (US$6.52m market cap). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Reported Earnings • May 16
First quarter 2024 earnings released: US$1.46 loss per share (vs US$2.61 loss in 1Q 2023) First quarter 2024 results: US$1.46 loss per share (improved from US$2.61 loss in 1Q 2023). Revenue: US$3.43m (up 22% from 1Q 2023). Net loss: US$2.08m (loss narrowed 31% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. New Risk • May 08
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Market cap is less than US$10m (US$8.35m market cap). Minor Risk Shareholders have been diluted in the past year (25% increase in shares outstanding). お知らせ • May 01
Precipio, Inc., Annual General Meeting, Jun 13, 2024 Precipio, Inc., Annual General Meeting, Jun 13, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect Kathleen D. LaPorte and Ron A. Andrews as ClassIII directors for terms to expire in 2027; to hold an advisory (non-binding) vote to approve named executive compensation; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the year ending December31, 2024; to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Reported Earnings • Mar 31
Full year 2023 earnings released: US$4.51 loss per share (vs US$10.73 loss in FY 2022) Full year 2023 results: US$4.51 loss per share (improved from US$10.73 loss in FY 2022). Revenue: US$15.2m (up 62% from FY 2022). Net loss: US$5.85m (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. お知らせ • Jan 02
Precipio, Inc. Announces Board Changes Precipio, Inc. welcomed Christina Valauri to its board of directors effective January 1, 2024. Ms. Valauri is joining Precipio’s board to support management’s understanding of and interaction with the capital markets, as the company look towards 2024 to be an important period for the company from both a business growth, and financial perspective. Ms. Valauri brings a 30-year proven track record as a senior healthcare analyst and has held leadership roles that include US and Global Head of Equity Research and Managing Director at Cantor Fitzgerald, and senior equity research management roles at firms including ING, Credit Lyonnais (acquired by Credit Agricole), and Natixis. She has been recognized by The Wall Street Journal’s “Best on The Street” All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public Affairs - Association of American Medical Colleges. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC. Her background in equity securities research has provided a deep base of experience in pharmaceutical, biotech, and med-tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs. Ms. Valauri currently serves as an Entrepreneur In Residence at Weill Cornell Medicine BioVenture eLab where she applies her skills and experience in life sciences and business to support the organization’s mission to foster an entrepreneurial ecosystem related to the innovations of researchers, and clinicians. Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University. After serving on Precipio’s board of directors for 6 years, Douglas Fisher, MD is stepping off the board to maintain a board of 7 directors and will remain as an observer moving forward. Reported Earnings • Nov 16
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$1.04 loss per share (improved from US$2.79 loss in 3Q 2022). Revenue: US$4.52m (up 104% from 3Q 2022). Net loss: US$1.46m (loss narrowed 54% from 3Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 26%. Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. お知らせ • Sep 22
Precipio Takes Final Step Towards Regaining Nasdaq Compliance Precipio, Inc. announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the company's common stock in order to regain compliance with the Nasdaq minimum bid price requirement of $1.00. A reverse split essentially means a decrease in the number of shares and a proportional increase in the value of the share price. Therefore, the reverse split in itself has no impact on the aggregate value of stock held by you as a shareholder. The primary goal of the reverse stock split is to increase the per share market price of the company’s common stock to meet the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market. As you may know, many individual investors, and some institutional investors, are prohibited from trading shares of companies below $2, and some are prohibited from trading shares below $5. The post-reverse stock split share price should enable the company to broaden its potential pool of investors to include both individual and institutional investors who face such restrictions. This is expected to increase demand for the stock. “I understand the disappointment many of our shareholders feel, and the negative sentiment attached to the reverse stock split. I urge you to look at our company performance as measured by revenues, margins and cash, and you will see a good story developing”, said Ilan Danieli, Chief Executive Officer. Major Estimate Revision • Aug 20
Consensus revenue estimates increase by 11% The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$13.7m to US$15.2m. Forecast losses expected to reduce from -US$0.34 to -US$0.33 per share. Healthcare industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$2.00 unchanged from last update. Share price was steady at US$0.36 over the past week. New Risk • Aug 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.7m free cash flow). Market cap is less than US$10m (US$9.92m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$3.6m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Reported Earnings • Aug 13
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: US$0.094 loss per share (in line with 2Q 2022). Revenue: US$3.53m (up 50% from 2Q 2022). Net loss: US$2.29m (loss widened 6.9% from 2Q 2022). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. New Risk • Jun 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.96m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$9.96m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.2m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.7m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap). お知らせ • May 24
Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190). While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician. Changes in isoform expression may happen over time during the course of treatment. The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab. Reported Earnings • May 14
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2023 results: US$0.13 loss per share (improved from US$0.20 loss in 1Q 2022). Revenue: US$2.82m (up 15% from 1Q 2022). Net loss: US$3.03m (loss narrowed 34% from 1Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 02
Full year 2022 earnings released: US$0.54 loss per share (vs US$0.40 loss in FY 2021) Full year 2022 results: US$0.54 loss per share (further deteriorated from US$0.40 loss in FY 2021). Revenue: US$9.41m (up 6.4% from FY 2021). Net loss: US$12.2m (loss widened 43% from FY 2021). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 16
Price target decreased to US$4.00 Down from US$7.00, the current price target is provided by 1 analyst. New target price is 400% above last closing price of US$0.80. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.37 next year compared to a net loss per share of US$0.40 last year. Reported Earnings • Nov 12
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$0.14 loss per share (further deteriorated from US$0.082 loss in 3Q 2021). Revenue: US$2.22m (down 1.4% from 3Q 2021). Net loss: US$3.18m (loss widened 71% from 3Q 2021). Revenue missed analyst estimates by 56%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 12
Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.14 loss in 2Q 2021) Second quarter 2022 results: US$0.094 loss per share (up from US$0.14 loss in 2Q 2021). Revenue: US$2.36m (flat on 2Q 2021). Net loss: US$2.14m (loss narrowed 29% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 04
Forecast to breakeven in 2023 The analyst covering Precipio expects the company to break even for the first time. New forecast suggests the company will make a profit of US$123.0k in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule. Reported Earnings • May 13
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$0.20 loss per share (down from US$0.081 loss in 1Q 2021). Revenue: US$2.45m (up 34% from 1Q 2021). Net loss: US$4.59m (loss widened 216% from 1Q 2021). Revenue missed analyst estimates by 49%. Earnings per share (EPS) also missed analyst estimates by 300%. Over the next year, revenue is forecast to grow 162%, compared to a 8.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to US$4.00 Down from US$7.00, the current price target is provided by 1 analyst. New target price is 281% above last closing price of US$1.05. Stock is down 46% over the past year. The company is forecast to post a net loss per share of US$0.21 next year compared to a net loss per share of US$0.40 last year. Reported Earnings • Apr 01
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: US$0.40 loss per share (up from US$0.85 loss in FY 2020). Revenue: US$8.85m (up 45% from FY 2020). Net loss: US$8.53m (loss narrowed 39% from FY 2020). Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) exceeded analyst estimates by 8.1%. Over the next year, revenue is forecast to grow 136%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 15
Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.21 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$2.25m (up 38% from 3Q 2020). Net loss: US$1.86m (loss narrowed 44% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 14
Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2020) The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$2.34m (up 79% from 2Q 2020). Net loss: US$3.01m (loss widened 34% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.78 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$1.82m (up 50% from 1Q 2020). Net loss: US$1.45m (loss narrowed 78% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Price Target Changed • May 03
Price target increased to US$7.00 Up from US$5.15, the current price target is provided by 1 analyst. New target price is 285% above last closing price of US$1.82. Stock is up 151% over the past year.